CPC G01N 33/5748 (2013.01) [C07K 16/18 (2013.01); C07K 16/30 (2013.01); G01N 33/577 (2013.01); G01N 33/582 (2013.01); C07K 2317/34 (2013.01)] | 8 Claims |
1. A method for the therapy control of a neuroendocrine tumour or prostate cancer in a subject comprising:
(a) determining the presence and/or absence or the level of Chromogranin A or a fragment thereof in a sample from said subject using an immunoassay method comprising the steps of:
(i) contacting said sample with a first antibody or an antigen-binding fragment thereof specific for Chromogranin A, and
(ii) a second antibody or an antigen-binding fragment thereof specific for Chromogranin A,
wherein the first antibody is produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231;
or the second antibody is produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232;
or the first antibody is produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231, and the second antibody is produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232;
under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof,
(c) detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A;
(d) adjusting the therapeutic treatment of the subject.
|